C5 and paroxysmal nocturnal hemoglobinuria: Further, before the 2007 US Food and Drug Administration (FDA) approval of eculizumab (Soliris), a complement component 5 (C5)-directed monoclonal antibody, only supportive care was available for patients with PNH [3,4,5].